News

Qilu Pharmaceutical launches Phase I clinical trials of a new lipid-lowering drug targeting PCSK9 siRNA On February 27, 2026, according to the webs...

Losing 19.7% weight in 24 weeks! Federal Pharmaceutical X Novo Nordisk GLP-1/GIP/GCG triple target agonist weight loss phase 1 study successful On ...

Eli Lilly announces the successful Phase I study of the combination of Tirzepatide and Yiqizhu monoclonal antibody On February 18, 2026, Lilly anno...

On February 16, 2026, Shiyao Group announced that its GLP-1/GIP receptor dual directional agonist peptide long-acting injection (SYH2082 injection)...

Brazil Customer Andre ordered over 30 different items of Peptides from BLOOM TECH. (totaling over $12,300) and established a cross-border referral ...

In today's era of rapid biotechnology advancement, scientists continue to unravel the mysteries of life at the microscopic level, developing nu...

In the field of obesity and metabolic disease treatment, Retatrutide -the world's first triple hormone receptor agonist-has garnered widespread...

Thai peptide customer Wanissa purchased four sample boxes of BLOOM TECH's Tirzepatide 20mg through a sales representative. She was delighted up...

Bloom Tech, as a manufacturer specializing in raw material production and processing, offers GS441524 in various forms including injections, tablet...

During the procurement process of GS-441524 raw materials by Activet Pharma Chr Olesen, in order to ensure compliance of the process and reliabilit...

Roche GLP-1R/GIPR agonist initiates phase III clinical trials On January 20, 2026, according to the US Clinical Trial Registry website, Roche launc...

Recently, Suzhou Ruibo Biotechnology Co., Ltd. (stock code: 06938. HK), a leading enterprise in small nucleic acid drugs, officially listed on the ...